| http://www.w3.org/ns/prov#value | - PAT, a key element in the FDA???s announcement, aims to increase the likelihood of defect-free pharmaceuticals by applying a risk-based approach that combines in-situ and other in-process quality measurement technologies alongside best practices that are designed to identify out-of-spec conditions as early in the production cycle as possible.
|
